These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 16735371)

  • 1. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
    Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY
    Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of cyclooxygenase-2,and matrix metalloproteinase-2 expression on prognosis of lung cancer].
    Zhang HZ; Lu ZQ; Xie DR; Li HG; Xiong LH; Zhang H; Chen XB
    Ai Zheng; 2004 Oct; 23(10):1190-3. PubMed ID: 15473933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer.
    Li L; Mei TH; Zhou XD; Zhang XG
    Ai Zheng; 2009 Jan; 28(1):60-3. PubMed ID: 19448419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
    Hsu CP; Shen GH; Ko JL
    Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
    Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
    J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
    Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M
    Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expressions of vascular endothelial growth factor C and matrix metalloproteinases-2 and prognosis of non-small cell lung carcinoma].
    Zhang HZ; Wei YP; Li HG; Wang M; Liu JG; Wu C
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Sep; 26(9):1307-10. PubMed ID: 16982442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer.
    Passlick B; Sienel W; Seen-Hibler R; Wöckel W; Thetter O; Mutschler W; Pantel K
    Clin Cancer Res; 2000 Oct; 6(10):3944-8. PubMed ID: 11051242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
    Milas I; Komaki R; Hachiya T; Bubb RS; Ro JY; Langford L; Sawaya R; Putnam JB; Allen P; Cox JD; McDonnell TJ; Brock W; Hong WK; Roth JA; Milas L
    Clin Cancer Res; 2003 Mar; 9(3):1070-6. PubMed ID: 12631609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
    Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
    Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer.
    Shou Y; Hirano T; Gong Y; Kato Y; Yoshida K; Ohira T; Ikeda N; Konaka C; Ebihara Y; Zhao F; Kato H
    Br J Cancer; 2001 Nov; 85(11):1706-12. PubMed ID: 11742492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Overexpression of COX-2 and its clinical significance in non-small cell lung cancer].
    Tian F; Wang TY; Gong M; Lu XM; Hu J; Wang J; Zhang CH
    Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):407-10. PubMed ID: 12895344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma.
    Wang Y; Fang S; Wei L; Wang R; Jin X; Wen D; Li Y; Guo W; Wang N; Zhang J
    Lung Cancer; 2005 Aug; 49(2):155-61. PubMed ID: 15949868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.
    Pritchard SC; Nicolson MC; Lloret C; McKay JA; Ross VG; Kerr KM; Murray GI; McLeod HL
    Oncol Rep; 2001; 8(2):421-4. PubMed ID: 11182067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation of matrix metalloproteinase-3 polymorphism to genetic susceptibility and lymph node metastasis of non-small cell lung cancer].
    Fang SM; Jin X; Li Y; Wang R; Guo W; Wang N; Zhang JH
    Ai Zheng; 2005 Mar; 24(3):305-10. PubMed ID: 15757531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival.
    Zheng S; Chang Y; Hodges KB; Sun Y; Ma X; Xue Y; Williamson SR; Lopez-Beltran A; Montironi R; Cheng L
    Anticancer Res; 2010 Mar; 30(3):713-8. PubMed ID: 20392988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer.
    Shao W; Wang W; Xiong XG; Cao C; Yan TD; Chen G; Chen H; Yin W; Liu J; Gu Y; Mo M; He J
    J Surg Oncol; 2011 Dec; 104(7):841-6. PubMed ID: 21721010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of COX-2 and MMP-9 in cervical carcinoma and their clinical significance].
    Luo CF; Zhu RQ; Wang H; Lu YL
    Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):526-30. PubMed ID: 18069634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.